Supervisory
Board
Dr Joachim Rothe, Chairman
Dr Joachim Rothe is responsible for Life Science Partner's (LSP) German office in Munich and currently serves on the supervisory boards of BioXell (I), Scion (USA), Affectis (G) and Morphochem (G). Before joining LSP in early 2002, he was a principal at MPM Capital in Cambridge, Mass., and managing director of MPM Capital GmbH based in Munich. In that capacity, Joachim Rothe served on the supervisory boards of Novirio Pharmaceuticals (now: Idenix, of which a majority stake was sold to Novartis in early 2003), Omrix and t. Breeders (now: Viacell). He also served as founding CFO of Idenix. Previously, he was at McKinsey & Company where he worked as an engagement manager on assignments in the chemical and pharmaceutical industries. During his time as a scientist with Hoffmann-La Roche in Basel, Switzerland, Joachim Rothe focused on molecular immunology and contributed to the preclinical development of an important drug candidate. Joachim Rothe holds a masters degree in Biochemistry from the Free University in Berlin, and he earned his PhD degree from the University of Freiburg in Germany, supervised by Georges Köhler (Nobel Prize 1984). He has authored numerous articles in leading scientific publications such as Nature.
Prof Dr Domenico Valerio
Dinko Valerio is a scientist and entrepreneur who founded and successfully built the biomedical company CrucellN.V., a NASDAQ- and Euronext listed company with a market capitalization over € 600 million. He was CEO ofCrucell N.V. from its foundation in 1993 until 2004. In 1999 he also founded Galapagos Genomics N.V. as aspin-out from Crucell N.V. Galapagos Genomics N.V. went public on the Euronext stock market in May of 2005.
Dinko holds a professorship in Gene Therapy at the Leiden University since 1992. In 1985 Dinko was a ‘visitingscientific specialist’ at Genentech Inc., San Francisco, USA. He was a post-doctoral fellow at the Salk Institute,San Diego, USA from 1986 to 1987. He received his Master of Science degree in Biology from University ofAmsterdam and completed his Ph.D. in Molecular Genetics with Honors at Leiden University in 1986. Hepublished over 100 scientific articles and is an inventor on 80 patents (issued from 11 patent-families).
back to team - further Supervisory Board members
Dr Joachim Rothe, Chairman
Dr Joachim Rothe is responsible for Life Science Partner's (LSP) German office in Munich and currently serves on the supervisory boards of BioXell (I), Scion (USA), Affectis (G) and Morphochem (G). Before joining LSP in early 2002, he was a principal at MPM Capital in Cambridge, Mass., and managing director of MPM Capital GmbH based in Munich. In that capacity, Joachim Rothe served on the supervisory boards of Novirio Pharmaceuticals (now: Idenix, of which a majority stake was sold to Novartis in early 2003), Omrix and t. Breeders (now: Viacell). He also served as founding CFO of Idenix. Previously, he was at McKinsey & Company where he worked as an engagement manager on assignments in the chemical and pharmaceutical industries. During his time as a scientist with Hoffmann-La Roche in Basel, Switzerland, Joachim Rothe focused on molecular immunology and contributed to the preclinical development of an important drug candidate. Joachim Rothe holds a masters degree in Biochemistry from the Free University in Berlin, and he earned his PhD degree from the University of Freiburg in Germany, supervised by Georges Köhler (Nobel Prize 1984). He has authored numerous articles in leading scientific publications such as Nature.
Prof Dr Domenico Valerio
Dinko Valerio is a scientist and entrepreneur who founded and successfully built the biomedical company CrucellN.V., a NASDAQ- and Euronext listed company with a market capitalization over € 600 million. He was CEO ofCrucell N.V. from its foundation in 1993 until 2004. In 1999 he also founded Galapagos Genomics N.V. as aspin-out from Crucell N.V. Galapagos Genomics N.V. went public on the Euronext stock market in May of 2005.
Dinko holds a professorship in Gene Therapy at the Leiden University since 1992. In 1985 Dinko was a ‘visitingscientific specialist’ at Genentech Inc., San Francisco, USA. He was a post-doctoral fellow at the Salk Institute,San Diego, USA from 1986 to 1987. He received his Master of Science degree in Biology from University ofAmsterdam and completed his Ph.D. in Molecular Genetics with Honors at Leiden University in 1986. Hepublished over 100 scientific articles and is an inventor on 80 patents (issued from 11 patent-families).
back to team - further Supervisory Board members